Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

BACKGROUND: Promotor hypermethylation of CpG islands is common in B cell precursor acute lymphoblastic leukemia (BCP-ALL) with mixed lineage leukemia (MLL) gene rearrangements. Hypomethylating agents (HMA) such as azacitidine (AZA) and decitabine (DEC) reduce DNA hypermethylation by incorporation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Roolf, C., Richter, A., Konkolefski, C., Knuebel, G., Sekora, A., Krohn, S., Stenzel, J., Krause, B. J., Vollmar, B., Murua Escobar, H., Junghanss, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936021/
https://www.ncbi.nlm.nih.gov/pubmed/29728108
http://dx.doi.org/10.1186/s13045-018-0607-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936021/
https://www.ncbi.nlm.nih.gov/pubmed/29728108
http://dx.doi.org/10.1186/s13045-018-0607-3

Ejemplares similares